Ascendis Pharma A/S $ASND Stock Acquired by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lifted its position in Ascendis Pharma A/S (NASDAQ:ASND) by 28,468.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,428 shares of the biotechnology company’s stock after buying an additional 5,409 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Ascendis Pharma A/S were worth $1,237,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Diversify Advisory Services LLC lifted its stake in Ascendis Pharma A/S by 10.0% during the 3rd quarter. Diversify Advisory Services LLC now owns 12,299 shares of the biotechnology company’s stock worth $2,787,000 after acquiring an additional 1,118 shares in the last quarter. New Wave Wealth Advisors LLC grew its position in Ascendis Pharma A/S by 7.8% in the 3rd quarter. New Wave Wealth Advisors LLC now owns 5,189 shares of the biotechnology company’s stock valued at $1,158,000 after acquiring an additional 375 shares in the last quarter. IFP Advisors Inc grew its position in Ascendis Pharma A/S by 54.8% in the 3rd quarter. IFP Advisors Inc now owns 667 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 236 shares in the last quarter. Burns Matteson Capital Management LLC acquired a new position in Ascendis Pharma A/S in the 3rd quarter valued at about $560,000. Finally, Assenagon Asset Management S.A. increased its stake in Ascendis Pharma A/S by 1,105.9% during the third quarter. Assenagon Asset Management S.A. now owns 17,305 shares of the biotechnology company’s stock worth $3,943,000 after purchasing an additional 15,870 shares during the period.

Insider Buying and Selling

In other news, Director Jean-Jacques Bienaimé bought 2,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the purchase, the director owned 2,900 shares of the company’s stock, valued at approximately $714,357. This represents a 222.22% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Mads Bodenhoff sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares in the company, valued at approximately $810,570. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. 40.00% of the stock is currently owned by corporate insiders.

Ascendis Pharma A/S Price Performance

ASND stock opened at $245.15 on Tuesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.99 and a quick ratio of 2.32. The firm has a market capitalization of $15.29 billion, a P/E ratio of 19.02 and a beta of 0.38. The business’s 50-day moving average is $242.53 and its two-hundred day moving average is $237.18. Ascendis Pharma A/S has a 1 year low of $188.07 and a 1 year high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The company had revenue of $387.22 million during the quarter, compared to analysts’ expectations of $376.75 million. Analysts anticipate that Ascendis Pharma A/S will post 3.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. UBS Group reissued a “buy” rating and set a $269.00 price target (down from $307.00) on shares of Ascendis Pharma A/S in a research report on Thursday, October 15th. Bank of America lowered their price objective on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating for the company in a research note on Monday, August 31st. BMO Capital Markets restated an “outperform” rating on shares of Ascendis Pharma A/S in a report on Thursday, September 10th. Wedbush reaffirmed an “outperform” rating and set a $327.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, September 1st. Finally, Citigroup cut their target price on shares of Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating on the stock in a research note on Monday. Nineteen investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $305.95.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve treatment convenience, maintain controlled drug exposure, and address unmet medical needs.

Its commercial products include SKYTROFA (lonape­gsomatropin-tcgd), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a once-daily therapy for adults with hypoparathyroidism.